A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
about
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedemaAnti-vascular endothelial growth factor for diabetic macular oedemaDiabetic macular edema: it is more than just VEGFUpdates on the Clinical Trials in Diabetic Macular EdemaRole of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implantINTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONSThe clinical utility of aflibercept for diabetic macular edemaAnti-VEGF Therapy and the Retina: An UpdatePerspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedemaThe role of aflibercept in the management of diabetic macular edemaLaser, intravitreal drug application, and surgery to treat diabetic eye diseaseDiabetic retinopathy: variations in patient therapeutic outcomes and pharmacogenomicsA review of therapies for diabetic macular oedema and rationale for combination therapyNovel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelinesDiabetic macular oedema: evidence-based treatment recommendations for Asian countries.Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.Diabetic macular edema: New promising therapies.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.New Therapeutic Approaches in Diabetic Retinopathy.Noninvasive Retinal Markers in Diabetic Retinopathy: Advancing from Bench towards BedsideThe role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy.Immediate effect of intravitreal injection of bevacizumab on intraocular pressure.Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates.Diabetic retinopathy: pathogenesis, clinical grading, management and future developments.Pathophysiology and treatment of diabetic retinopathy.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Current treatments in diabetic macular oedema: systematic review and meta-analysisBevacizumab for the management of diabetic macular edemaGlucocorticoid induction of occludin expression and endothelial barrier requires transcription factor p54 NONORanibizumab: the first vascular endothelial growth factor inhibitor approved for the treatment of diabetic macular edema.Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: a systemic review and Meta-analysis.Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.Diabetic retinopathy in sub-Saharan Africa: meeting the challenges of an emerging epidemic.Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5).Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT study (report 4).Impact of insulin treatment in diabetic macular edema therapy in type 2 diabetes.Ocular complications of diabetes mellitus.Anti-vascular endothelial growth factor therapy for diabetic macular edemaEvolving strategies in the management of diabetic retinopathy
P2860
Q24187587-4534D114-77B0-497A-B234-57B29D214322Q24193083-62E6E59A-449F-467E-BA48-95862CA6EA78Q26745914-E188D658-927C-4DCF-92CB-5EE5D6663673Q26767100-9BA93479-A823-46F1-8A16-55D710C85198Q26775853-4CF41587-2B94-4BEC-A234-84FFEC6EFBCFQ26782198-7EBB1536-52AE-418A-A436-DF3D67DB8873Q26783575-E7BCC62F-15C7-4794-A8D2-64B7E2A33513Q26784605-C8D53672-7421-49D4-AAB5-021D083A0710Q26786012-6A299A07-7606-4481-A377-DD7422940A86Q26798348-B5047B41-1647-4864-B4EA-5CCCBBA8447CQ26995365-4D1E29DD-E90A-4480-ABF8-7198E48BED54Q26998543-CC807570-0AA3-4BBF-93B4-FB014F8056F2Q27008325-6028C78B-8FF4-4AF9-8666-2B5BB588D8B0Q28066675-97A5DADD-7270-4B9D-80D8-5A0C6A4ADB4EQ28075473-4E29EEC0-5EB3-436B-8FF4-5C3BA93F9B4FQ30101045-060EDACD-8CC1-42B4-A639-B5C0748BCE28Q30244247-DA592D8C-9853-44BF-8168-E7C44D59342EQ30415630-B42DD0EE-36DA-45A4-8E45-7B5D515601B1Q30490738-77505AF6-E208-4FC8-8B9E-904EAD2E0F35Q33583037-1F6305AD-F792-4ACE-81E6-9B562FE4860AQ33608021-F373033E-3C8D-426A-9F4F-961A66F70AEFQ33683197-4D9B45C8-D583-4C9A-AAE9-46FE2C9CC40FQ33968693-8C4FDC31-1AC2-4DC6-B82A-47F21952EC02Q34062356-CEDC3DD3-43F9-4153-9AC5-3AA2A793D460Q34498235-B2ADCC81-5052-4DF5-9827-69CD27A02CDFQ34528134-7793BA4C-07BB-44CE-BAA4-0C6A0524C80EQ34558187-A8104979-04C6-4450-AC61-770F0C743B6CQ34606190-6250A355-4781-41D7-BCA2-1A7345635EF7Q34675149-33A0A465-B39A-4488-B877-55536B2D34D4Q34703697-B772065A-D0C3-4044-BD3D-D84F0A0402C8Q34711043-4054B63D-830F-4AEC-A64B-4C99D75C94F3Q34735711-E1F59DF1-D677-42DF-AE49-8E8E8A834E81Q34758061-063066B2-8FAD-46C8-B2F0-A6B413B51CE5Q34790721-2BB30A99-5656-440E-97F7-08AFBC5950EFQ34792137-5ED2457F-23C1-4047-9393-06C190006EFFQ34980970-F1DBEA2B-968A-4E98-9104-4664BEFD3B62Q35007582-1BF46F89-96BA-4317-80D1-F4CC70910FA7Q35049903-5C154DDC-9943-4FE8-8817-735283570EE4Q35064343-A829051F-8F75-44DB-B14E-F257633E8F05Q35067102-5B5C789A-0109-4D3D-A893-4809676CA316
P2860
A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A 2-year prospective randomize ...... dema: 24-month data: report 3.
@ast
A 2-year prospective randomize ...... dema: 24-month data: report 3.
@en
A 2-year prospective randomize ...... l bevacizumab or laser therapy
@nl
type
label
A 2-year prospective randomize ...... dema: 24-month data: report 3.
@ast
A 2-year prospective randomize ...... dema: 24-month data: report 3.
@en
A 2-year prospective randomize ...... l bevacizumab or laser therapy
@nl
prefLabel
A 2-year prospective randomize ...... dema: 24-month data: report 3.
@ast
A 2-year prospective randomize ...... dema: 24-month data: report 3.
@en
A 2-year prospective randomize ...... l bevacizumab or laser therapy
@nl
P2093
P50
P1433
P1476
A 2-year prospective randomize ...... edema: 24-month data: report 3
@en
P2093
Andrew Kaines
Michel Michaelides
Philip G Hykin
Ranjan Rajendram
Richard David Leslie
Robin D Hamilton
Simona Degli Esposti
P304
P356
10.1001/ARCHOPHTHALMOL.2012.393
P407
P577
2012-08-01T00:00:00Z